Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2984_Библиотеки_им_академика_М_И_Перельмана
.pdf
Karolina Pierzynowska, Estera Rintz, Lidia Gaffke et al.
92
Rigney, S; Christianson, TM; Tiger, PMN; Lo, MJ; Holtzinger, J;
Fitzpatrick, PA; LeBowitz, JH; Bullens, S; Crawford, BE; Bunting,
S. Clearance of Heparan Sulfate and Attenuation of CNS Pathology
by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
Mol. Ther. Methods. Clin. Dev. 2017, 6, 43–53.
[90] Grover, A; Crippen-Harmon, D; Nave, L; Vincelette, J; Wait, JCM;
Melton, AC; Lawrence, R; Brown, JR; Webster, KA; Yip, BK;
Baridon, B; Vitelli, C; Rigney, S; Christianson, TM; Tiger, PMN;
Lo, MJ; Holtzinger, J; Shaywitz, AJ; Crawford, BE; Fitzpatrick, PA;
LeBowitz, JH; BullensS; Aoyagi-Scharber, M; Bunting, S; O'Neill,
CA, Pinkstaff J, Bagri, A. Translational studies of intravenous and
intracerebroventricular routes of administration for CNS cellular
biodistribution for BMN 250, an enzyme replacement therapy for
the treatment of Sanfilippo type B. Drug Deliv. Transl. Res. 2020,
10, 425-439.
[91] Clarke, D; Pearse, Y; Kan, S; Le, S. Q; Sanghez, V; Cooper, JD;
Dickson, PI; Iacovino, M. Genetically Corrected iPSC-Derived
Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect
CNS Disease in Sanfilippo B Mice. Mol. Ther. Methods Clin. Dev.
2018, 10, 113–127.
[92] Whitley, CB; Vijay, S; Yao, B; Pineda, M; Parker, GJM; Rojas-
Caro, S; Zhang, X; Dai, Y; Cinar, A; Bubb, G; Patki, KC; Escolar,
ML. Final results of the phase 1/2, open-label clinical study of
intravenous recombinant human N-acetyl-α-d-glucosaminidase
(SBC-103) in children with mucopolysaccharidosis IIIB. Mol.
Genet. Metab. 2019, 126, 131-138.
[93] Willing, AE; Garbuzova-Davis, SN; Zayko, O; Derasari, HM;
Rawls, AW; James, CR; Mervis, RF; Sanberg, CD; Kuzmin-
Nichols, N; Sanberg, PR. Repeated administrations of human
umbilical cord blood cells improve disease outcomes in a mouse
model of Sanfilippo syndrome type III B. Cell. Transplant. 2014,
23, 1613-1630.
[94] Welling, L; Marchal, JP; van Hasselt, P; van der Ploeg, AT;
Wijburg, FA; Boelens, JJ. Early umbilical cord blood-derived stem
https://t.me/medicina_free
Mucopolysaccharidosis Type III (Sanfilippo Disease) …
93
cell transplantation does not prevent neurological deterioration in
mucopolysaccharidosis type III. JIMD. Rep. 2015, 18, 63-68.
[95] Aldenhoven, M; Jones, SA; Bonney, D; Borrill, RE; Coussons, M;
Mercer, J; Bierings, MB; Versluys, B; van Hasselt, PM; Wijburg,
FA; van der Ploeg, AT; Wynn, RF; Boelens, JJ. Hematopoietic Cell
Transplantation for Mucopolysaccharidosis Patients Is Safe and
Effective: Results after Implementation of International Guidelines.
Biol. Blood Marrow. Transplant. 2015, 21, 1106–1109.
[96] Rastall, DP; Amalfitano, A. Recent advances in gene therapy for
lysosomal storage disorders. Appl. Clin. Genet. 2015, 8, 157–169.
[97] Ruzo, A; Marco, S; Garcia, M; Villacampa, P; Ribera, A; Ayuso, E;
Maggioni, L; Mingozzi, F; Haurigot, V; Bosch, F. Correction of
pathological accumulation of glycosaminoglycans in central nervous
system and peripheral tissues of MPSIIIA mice through systemic
AAV9 gene transfer. Hum. Gene Ther. 2012, 23, 1237-1246.
[98] Heldermon, CD; Qin, EY; Ohlemiller, KK; Herzog, ED; Brown, JR;
Vogler, C; Hou, W; Orrock, JL; Crawford, BE; Sands, MS. Disease
correction by combined neonatal intracranial AAV and systemic
lentiviral gene therapy in Sanfilippo syndrome type B mice. Gene
Ther. 2013, 20, 913-921.
[99] Murrey, DA; Naughton, BJ; Duncan, FJ; Meadows, AS; Ware, TA;
Campbel, K; Bremer, WG; Walker, C; Goodchild, L; Bolon, B; La
Perle, K; Flanigan, K; McBride, KL; McCarty, DM; Fu, H.
Feasibility and safety of systemic rAAV9-hNAGLU delivery for
treating MPS IIIB: Toxicology, bio-distribution and immunological
assessments in primates. Hum. Gene Ther. Clin. Dev. 2014, 25, 72-
84.
[100] Tardieu, M; Zerah, M; Husson, B; de Bournonville, S; Deiva, K;
Adamsbaum, C; Vincent, F; Hocquemiller, M; Broissand, C; Furlan,
V; Ballabio, A; Fraldi, A; Crystal, RG; Baugnon, T; Roujeau T;
Heard O Danos, JM. Intracerebral administration of adeno-
associated viral vector serotype rh.10 carrying human SGSH and
SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA
https://t.me/medicina_free
Karolina Pierzynowska, Estera Rintz, Lidia Gaffke et al.
94
disease: results of a phase I/II trial. Hum. Gene Ther. 2014, 25, 506-
16.
[101] Srivastava, A. In vivo tissue-tropism of adeno-associated viral
vectors. Curr. Opin. Virol. 2016, 21, 75–80.
[102] Naso, MF; Tomkowicz, B; Perry, WL; Strohl, WR. Adeno-
Associated Virus (AAV) as a Vector for Gene Therapy. Bio Drugs.
2017, 31, 317–334.
[103] Ribera, A; Haurigot, V; Garcia, M; Marcó, S; Motas, S; Villacampa,
P; Maggioni, L; León, X; Molas, M; Sánchez, V; Muñoz, S;
Leborgne, C; Moll, X; Pumarola, M; Mingozzi, F; Ruberte, J; Añor,
S; Bosch, F. Biochemical, histological and functional correction of
mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene
therapy. Hum. Mol. Genet. 2015, 24, 2078–2095.
[104] Roca, C; Motas, S; Marcó, S; Ribera, A; Sánchez, V; Sánchez, X;
Bosch, F. 17). Disease correction by AAV-mediated gene therapy in
a new mouse model of mucopolysaccharidosis type IIID. Hum. Mol.
Genet. 2017, 26, 1535–1551.
[105] Lau, AA; Hemsley, KM. Adeno-associated viral gene therapy for
mucopolysaccharidoses exhibiting neurodegeneration. J. Mol. Med.
2017, 95, 1043–1052.
[106] Meadows, AS; Duncan, FJ; Camboni, M; Waligura, K;
Montgomery, CL; Zaraspe, K; Zaraspe, K; Naughton, BJ; Bremer,
WG; Shilling, C; Walker, CM; Bolon, B; Flanigan, KM; McBride,
KL; McCarty, DM; Fu, H. A GLP-compliant toxicology and
biodistribution study: systemic delivery of a rAAV9 vector for the
treatment of mucopolysaccharidosis IIIB. Hum. Gene Ther. Clin.
Dev. 2015, 26, 228-242.
[107] Fu, H; Meadows, AS; Ware, T; Mohney, RP; McCarty, DM. Near-
Complete Correction of Profound Metabolomic Impairments
Corresponding to Functional Benefit in MPS IIIB Mice after IV
rAAV9-hNAGLU Gene Delivery. Mol. Ther. 2017, 25, 792–802.
[108] Duncan, FJ; Naughton, BJ; Zaraspe, K; Murrey, DA; Meadows, AS;
Clark, KR; Newsom, DE; White, P; Fu, H; McCarty, DM. Broad
Functional Correction of Molecular Impairments by Systemic
https://t.me/medicina_free
Mucopolysaccharidosis Type III (Sanfilippo Disease) …
95
Delivery of scAAVrh74-hSGSH Gene Delivery in MPS IIIA Mice.
Mol. Ther. 2015, 23, 638–647.
[109] Fu, H; Cataldi, MP; Ware, TA; Zaraspe, K; Meadows, AS; Murrey,
DA; McCarty, DM. Functional correction of neurological and
somatic disorders at later stages of disease in MPS IIIA mice by
systemic scAAV9-hSGSH gene delivery. Hum. Gene Ther. Clin.
Dev. 2016, 3, 16036.
[110] Gilkes, JA; Bloom, MD; Heldermon, CD. Preferred transduction
with AAV8 and AAV9 via thalamic administration in the MPS IIIB
model: A comparison of four rAAV serotypes. Mol. Genet. Metab.
Rep. 2015, 6, 48–54.
[111] Gilkes, JA; Bloom, MD; Heldermon, CD. Mucopolysaccharidosis
IIIB confers enhanced neonatal intracranial transduction by AAV8
but not by 5, 9 or rh10. Gene Ther. 2016, 23(3), 263–271.
[112] Tordo, J; O’Leary, C; Antunes, ASLM; Palomar, N; Aldrin-Kirk, P;
Basche, M; Bennett, A; D'Souza, Z; Gleitz, H; Godwin, A; Holley,
RJ; Parker, H; Liao, AY; Rouse, P; Youshani, AS; Dridi, L; Martins,
C; Levade, T; Stacey, KB; Davis, DM; Dyer, A; Clément, N;
Björklund, T; Ali, RR; Agbandje-McKenna, M; Rahim, AA;
Pshezhetsky, A; Waddington, SN; Linden, RM; Bigger, BW;
Henckaerts, E. A novel adeno-associated virus capsid with enhanced
neurotropism corrects a lysosomal transmembrane enzyme
deficiency. Brain. 2018, 141, 2014–2031.
[113] Winner, LK; Beard, H; Hassiotis, S; Lau, AA; Luck, A. J;
Hopwood, JJ; Hemsley, KM. A Preclinical Study Evaluating
AAVrh10-Based Gene Therapy for Sanfilippo Syndrome. Hum.
Gene Ther. 2016, 27, 363–375.
[114] Tardieu, M; Zérah, M; Gougeon, ML; Ausseil, J; de Bournonville,
S; Husson, B; Zafeiriou, D; Parenti, G; Bourget, P; Poirier, B;
Furlan, V; Artaud, C; Baugnon, T; Roujeau, T; Crystal, RG; Meyer,
C; Deiva, K; Heard, JM. Intracerebral gene therapy in children with
mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase
1/2 clinical trial. Lancet Neurol. 2017, 16, 712–720.
https://t.me/medicina_free
Karolina Pierzynowska, Estera Rintz, Lidia Gaffke et al.
96
[115] Gray, AL; O’Leary, C; Liao, A; Agundez, L; Youshani, A. S; Gleitz,
HF; Parker, H; Taylor, JT; Danos, O; Hocquemiller, M; Palomar, N;
Linden, RM; Henckaerts, E; Holley, RJ; Bigger, B. An improved
AAV vector for neurological correction of the mouse model of
Mucopolysaccharidosis IIIA. Hum. Gene Ther. 2019, 30, 1052-
1066.
[116] Clarke, D; Pearse, Y; Kan, S; Le, SQ; Sanghez, V; Cooper, JD;
Dickson, PI; Iacovino, M. Genetically Corrected iPSC-Derived
Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect
CNS Disease in Sanfilippo B Mice. Mol. Ther. Methods Clin. Dev.
2018, 10, 113–127.
[117] Holley RJ; Ellison, SM; Fil D, O'Leary, C; McDermott, J; Senthivel,
N; Langford-Smith, AWW; Wilkinson, FL; D'Souza, Z; Parker, H;
Liao, A; Rowlston, S; Gleitz, HFE; Kan, SH; Dickson, PI; Bigger,
BW. Macrophage enzyme and reduced inflammation drive brain
correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
Brain. 2018, 141, 99-116.
[118] Jakobkiewicz-Banecka, J; Piotrowska, E; Gabig-Ciminska, M;
Borysiewicz, E; Slominska-Wojewodzka, M; Narajczyk, M;
Wegrzyn, A; Wegrzyn, G. Substrate reduction therapies for
mucopolysaccharidoses. Curr. Pharm. Biotechnol. 2011, 12, 1860-
1865.
[119] Kaidonis, X; Liaw, WC; Roberts, AD; Ly, M; Anson, D; Byers, S.
Gene silencing of EXTL2 and EXTL3 as a substrate deprivation
therapy for heparan sulphate storing mucopolysaccharidoses. Eur. J.
Hum. Genet. 2010, 18, 194-199.
[120] Dziedzic, D; Wegrzyn, G; Jakobkiewicz-Banecka, J. Impairment of
glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA
cells by using siRNA: a potential therapeutic approach for
Sanfilippo disease. Eur. J. Hum. Genet. 2010, 18, 200-205.
[121] Canals, I; Benetó, N; Cozar, M; Vilageliu, L; Grinberg, D. EXTL2
and EXTL3 inhibition with siRNAs as a promising substrate
reduction therapy for Sanfilippo C syndrome. Sci. Rep. 2015, 8, 5,
13654.
https://t.me/medicina_free
Mucopolysaccharidosis Type III (Sanfilippo Disease) …
97
[122] Robert, AL; Thomas, BJ; Wilkinson, AS; Fletcher, JM; Byers, S.
Inhibition of glycosaminoglycan synthesis using rhodamine B in a
mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res.
2006, 60, 309-314.
[123] Roberts, AL; Rees, MH; Klebe, S; Fletcher, JM; Byers, S.
Improvement in behaviour after substrate deprivation therapy with
rhodamine B in a mouse model of MPS IIIA. Mol. Genet. Metab.
2007, 92, 115-121.
[124] Roberts, AL; Fletcher, JM; Moore, L; Byers, S. Trans-generational
exposure to low levels of rhodamine B does not adversely affect
litter size or liver function in murine mucopolysaccharidosis type
IIIA. Mol. Genet. Metab. 2010, 101, 208-213.
[125] Derrick-Roberts, AL; Marais, W; Byers, S. Rhodamine B and 2-
acetamido-1;3;6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose (F-
GlcNAc) inhibit chondroitin/dermatan and keratan sulphate
synthesis by different mechanisms in bovine chondrocytes. Mol.
Genet. Metab. 2012, 106, 214-220.
[126] Piotrowska, E; Jakobkiewicz-Banecka, J; Baranska, S; Tylki-
Szymanska, A; Czartoryska, B; Wegrzyn, A; Wegrzyn, G.
Genistein-mediated inhibition of glycosaminoglycan synthesis as a
basis for gene expression-targeted isoflavone therapy for
mucopolysaccharidoses. Eur. J. Hum. Genet. 2006, 14, 846-852.
[127] Jakobkiewicz-Banecka, J; Piotrowska, E; Narajczyk, M; Baranska,
S; Wegrzyn, G. Genistein-mediated inhibition of glycosaminoglycan
synthesis; which corrects storage in cells of patients suffering from
mucopolysaccharidoses; acts by influencing an epidermal growth
factor-dependent pathway. J. Biomed. Sci. 2009, 16; 26.
[128] Wegrzyn, A. Gene expression-targeted isoflavone therapy. IUBMB.
Life. 2012, 64, 307-315.
[129] Arfi, A; Richard, M; Gandolphe, C; Scherman, D. Storage
correction in cells of patients suffering from mucopolysaccharidoses
types IIIA and VII after treatment with genistein and other
isoflavones. J. Inherit. Metab. Dis. 2010, 33, 61-67.
https://t.me/medicina_free
Karolina Pierzynowska, Estera Rintz, Lidia Gaffke et al.
98
[130] Kloska, A; Jakobkiewicz-Banecka, J; Narajczyk, M; Banecka-
Majkutewicz, Z; Wegrzyn, G. Effects of flavonoids on
glycosaminoglycan synthesis: implications for substrate reduction
therapy in Sanfilippo disease and other mucopolysaccharidoses.
Metab. Brain Dis. 2011, 26, 1-8.
[131] Otomo, T; Hossain, MA; Ozono, K; Sakai, N. Genistein reduces
heparan sulfate accumulation in human mucolipidosis II skin
fibroblasts. Mol. Genet. Metab. 2012, 105, 266-269.
[132] Moskot, M; Jakobkiewicz-Banecka, J; Kloska, A; Smolinska, E;
Mozolewski, P; Malinowska, M; Rychlowski, M; Banecki, B;
Wegrzyn, G; Gabig-Ciminska, M. Modulation of expression of
genes involved in glycosaminoglycan metabolism and lysosome
biogenesis by flavonoids. Sci. Rep. 2015, 5, 9378.
[133] Kingma, SD; Wagemans, T; IJlst, L; Wijburg, FA; van Vlies, N.
Genistein increases glycosaminoglycan levels in
mucopolysaccharidosis type I cell models. J. Inherit. Metab. Dis.
2014, 37, 813-821.
[134] Fumić, B; Končić, MZ; Jug, M. Therapeutic Potential of
Hydroxypropyl-β-Cyclodextrin-Based Extract of Medicago sativa in
the Treatment of Mucopolysaccharidoses. Planta Med. 2017, 83, 40-
50.
[135] Moskot, M; Montefusco, S; Jakobkiewicz-Banecka, J; Mozolewski,
P; Wegrzyn, A; Di Bernardo, D; Wegrzyn, G; Medina, DL;
Ballabio, A; Gabig-Ciminska, M. The phytoestrogen genistein
modulates lysosomal metabolism and transcription factor EB
(TFEB) activation. J. Biol. Chem. 2014, 289, 17054-17069.
[136] Fumić, B; Jablan, J; Cinčić, D; Zovko, Končić M; Jug, M.
Cyclodextrin encapsulation of daidzein and genistein by grinding:
implication on the glycosaminoglycan accumulation in
mucopolysaccharidosis type II and III fibroblasts. J. Microencapsul.
2018, 35, 1-12.
[137] Malinowska, M; Wilkinson, FL; Bennett, W; Langford-Smith, KJ;
O'Leary, HA; Jakobkiewicz-Banecka, J; Wynn, R; Wraith, JE;
Wegrzyn, G; Bigger, BW. Genistein reduces lysosomal storage in
https://t.me/medicina_free
Mucopolysaccharidosis Type III (Sanfilippo Disease) …
99
peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet.
Metab. 2009, 98, 235-242.
[138] Malinowska, M; Wilkinson, FL; Langford-Smith, KJ; Langford-
Smith, A; Brown, JR; Crawford, BE; Vanier, MT; Grynkiewicz, G;
Wynn, RF; Wraith, JE; Wegrzyn, G; Bigger, BW. Genistein
improves neuropathology and corrects behaviour in a mouse model
of neurodegenerative metabolic disease. PLoS. One. 2010, 5,
e14192.
[139] Friso, A; Tomanin, R; Salvalaio, M; Scarpa, M. Genistein reduces
glycosaminoglycan levels in a mouse model of
mucopolysaccharidosis type II. Br. J. Pharmacol. 2010, 159, 1082-
91.
[140] Kingma, SD; Wagemans, T; IJlst, L; Seppen, J; Gijbels, MJ;
Wijburg, FA; van Vlies, N. Adverse effects of genistein in a
mucopolysaccharidosis type I mouse model. JIMD. Rep. 2015, 23,
77-83.
[141] Piotrowska, E; Jakobkiewicz-Banecka, J; Tylki-Szymanska, A;
Liberek, A; Maryniak, A; Malinowska, M; Czartoryska, B; Puk, E;
Kloska, A; Liberek, T; Baranska, S; Wegrzyn, A; Wegrzyn, G.
Genistin-rich soy isoflavone extract in substrate reduction therapy
for Sanfilippo syndrome: An open-label; pilot study in 10 pediatric
patients. Curr. Ther. Res. Clin. Exp. 2008, 69, 166-179.
[142] Piotrowska, E; Jakobkiewicz-Banecka, J; Maryniak, A; Tylki-
Szymanska, A; Puk, E; Liberek, A; Wegrzyn, A; Czartoryska, B;
Slominska-Wojewodzka, M; Wegrzyn, G. Two-year follow-up of
Sanfilippo Disease patients treated with a genistein-rich isoflavone
extract: assessment of effects on cognitive functions and general
status of patients. Med. Sci. Monit. 2011, 17, CR196-202.
[143] Marucha, J; Tylki-Szymanska, A; Jakobkiewicz-Banecka, J;
Piotrowska, E; Kloska, A; Czartoryska, B; Wegrzyn, G.
Improvement in the range of joint motion in seven patients with
mucopolysaccharidosis type II during experimental gene expression-
targeted isoflavone therapy (GET IT). Am. J. Med. Genet. A. 2011,
155A,2257-2262.
https://t.me/medicina_free
Karolina Pierzynowska, Estera Rintz, Lidia Gaffke et al.
100
[144] MalinovA, V; Wegrzyn, G; Narajczyk, M. The use of elevated doses
of genistein-rich soy extract in the gene expression-targeted
isoflavone therapy for Sanfilippo disease patients. JIMD. Rep. 2012,
5; 21-25.
[145] Delgadillo, V; O'Callaghan, M; Mdel, M; Artuch, R; Montero, R;
Pineda, M. Genistein supplementation in patients affected by
Sanfilippo disease. J. Inherit. Metab. Dis. 2011, 34, 1039-1044.
[146] de Ruijter, J; Valstar, MJ; Narajczyk, M; Wegrzyn, G; Kulik, W;
Ijlst, L; Wagemans, T; van der Wal, MV; Wijburg, FA. Genistein in
Sanfilippo disease: a randomized controlled crossover trial. Ann.
Neurol. 2012, 71, 110-120.
[147] Kim, KH; Dodsworth, C; Paras, A; Burton, BK. High dose genistein
aglycone therapy is safe in patients with mucopolysaccharidoses
involving the central nervous system. Mol. Genet. Metab. 2013, 109,
382-385.
[148] Cox, TM; Aerts, JM; Andria, G; Beck, M; Belmatoug, N; Bembi, B;
Chertkoff, R; Vom Dahl, S; Elstein, D; Erikson, A; Giralt, M;
Heitner, R; Hollak, C; Hrebicek, M; Lewis, S; Mehta, A; Pastores,
GM; Rolfs, A; Miranda, MC; Zimran, A. The role of the iminosugar
N-butyldeoxynojirimycin (miglustat) in the management of type I
(non-neuronopathic) Gaucher disease: a position statement. J.
Inherit. Metab. Dis. 2003, 26, 513-526.
[149] Lyseng-Williamson, KA. Miglustat: a review of its use in Niemann-
Pick disease type C. Drugs. 2014, 74, 61-74.
[150] Kaidonis, X; Byers, S; Ranieri, E; Sharp, P; Fletcher, J; Derrick-
Roberts, A. N-butyldeoxynojirimycin treatment restores the innate
fear response and improves learning in mucopolysaccharidosis IIIA
mice. Mol. Genet. Metab. 2016, 118, 100-110.
[151] Guffon, N; Bin-Dorel, S; Decullier, E; Paillet, C; Guitton, J;
Fouilhoux, A. Evaluation of miglustat treatment in patients with
type III mucopolysaccharidosis: a randomized; double-blind;
placebo-controlled study. J. Pediatr. 2011, 159, 838-844.
[152] Matalonga, L; Arias, A; Coll, MJ; Garcia-Villoria, J; Gort, L; Ribes,
A. Treatment effect of coenzyme Q (10) and an antioxidant cocktail
https://t.me/medicina_free
Mucopolysaccharidosis Type III (Sanfilippo Disease) …
101
in fibroblasts of patients with Sanfilippo disease. J. Inherit. Metab.
Dis. 2014, 37, 439-446.
[153] Matos, L; Canals, I; Dridi, L; Choi, Y; Prata, MJ; Jordan, P; Desviat,
LR; Pérez, B; Pshezhetsky, AV; Grinberg, D; Alves, S; Vilageliu, L.
Therapeutic strategies based on modified U1 snRNAs and
chaperones for Sanfilippo C splicing mutations. Orphanet J. Rare
Dis. 2014, 9, 180.
[154] Gómez-Grau, M; Garrido, E; Cozar, M; Rodriguez-Sureda, V;
Domínguez, C; Arenas, C; Gatti, RA; Cormand, B; Grinberg, D;
Vilageliu, L. Evaluation of Aminoglycoside and Non-
Aminoglycoside Compounds for Stop-Codon Readthrough Therapy
in Four Lysosomal Storage Diseases. PLoS One. 2015, 10,
e0135873.
[155] Pierzynowska, K; Gaffke, L; Podlacha, M; Brokowska, J; Węgrzyn,
G. Mucopolysaccharidosis and autophagy: controversies on the
contribution of the process to the pathogenesis and possible
therapeutic applications. Neuromolecular. Med. 2020, 22, 25-30.
[156] Lotfi, P; Tse, DY; Di Ronza, A; Seymour, ML; Martano, G; Cooper,
JD; Pereira, FA; Passafaro, M; Wu, SM; Sardiello, M. Trehalose
reduces retinal degeneration; neuroinflammation and storage burden
caused by a lysosomal hydrolase deficiency. Autophagy. 2018, 14,
1419-1434.
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана